ProShare Advisors’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$456K Sell
32,582
-879
-3% -$12.3K ﹤0.01% 1174
2025
Q1
$455K Sell
33,461
-8,364
-20% -$114K ﹤0.01% 1145
2024
Q4
$852K Buy
41,825
+9,877
+31% +$201K ﹤0.01% 983
2024
Q3
$931K Buy
31,948
+7,150
+29% +$208K ﹤0.01% 838
2024
Q2
$576K Sell
24,798
-6,407
-21% -$149K ﹤0.01% 906
2024
Q1
$640K Buy
31,205
+2,820
+10% +$57.9K ﹤0.01% 954
2023
Q4
$609K Buy
28,385
+4,053
+17% +$87K ﹤0.01% 932
2023
Q3
$502K Buy
24,332
+109
+0.4% +$2.25K ﹤0.01% 912
2023
Q2
$715K Buy
24,223
+1,937
+9% +$57.2K ﹤0.01% 808
2023
Q1
$513K Sell
22,286
-4,622
-17% -$106K ﹤0.01% 901
2022
Q4
$748K Buy
26,908
+4,119
+18% +$115K ﹤0.01% 806
2022
Q3
$700K Buy
22,789
+615
+3% +$18.9K ﹤0.01% 796
2022
Q2
$653K Sell
22,174
-9,707
-30% -$286K ﹤0.01% 863
2022
Q1
$1.03M Sell
31,881
-7,521
-19% -$242K ﹤0.01% 913
2021
Q4
$1.76M Sell
39,402
-435
-1% -$19.4K ﹤0.01% 797
2021
Q3
$2.01M Sell
39,837
-5,525
-12% -$279K 0.01% 712
2021
Q2
$3.56M Buy
45,362
+11,785
+35% +$924K 0.01% 571
2021
Q1
$1.92M Buy
33,577
+1,139
+4% +$65K 0.01% 712
2020
Q4
$2.72M Buy
32,438
+7,651
+31% +$641K 0.01% 566
2020
Q3
$888K Sell
24,787
-637
-3% -$22.8K ﹤0.01% 754
2020
Q2
$615K Buy
25,424
+9,145
+56% +$221K ﹤0.01% 862
2020
Q1
$285K Sell
16,279
-10,987
-40% -$192K ﹤0.01% 891
2019
Q4
$475K Sell
27,266
-4,124
-13% -$71.8K ﹤0.01% 1086
2019
Q3
$481K Sell
31,390
-1,299
-4% -$19.9K ﹤0.01% 999
2019
Q2
$679K Sell
32,689
-4,522
-12% -$93.9K ﹤0.01% 901
2019
Q1
$864K Buy
37,211
+226
+0.6% +$5.25K 0.01% 830
2018
Q4
$764K Buy
+36,985
New +$764K 0.01% 789